Chinese Firms Gain Prominence in Oncology at ASCO 2026, Highlighting Global Biopharma Collaboration
At the ASCO 2026 conference, Chinese biotech and pharmaceutical companies have taken a prominent role in the global oncology landscape. Companies like Betta Pharmaceuticals and Xcovery have been collaborating on innovative cancer treatments, such as the next-generation ALK inhibitor X-396 for lung cancer. This partnership exemplifies the growing integration of Chinese firms into the global biopharma industry, driven by advancements in precision medicine and regulatory frameworks that support rapid innovation. 
